No Data
Zhitong Hong Kong Stock Early Knowledge | The Ministry of Industry and Information Technology released the key points of automotive standardization work for 2025, ahead of schedule conducting research on the standardization needs of new business formats s
The Ministry of Industry and Information Technology released the key points for vehicle standardization work in 2025. It proposed to proactively layout standards research in cutting-edge fields. Analyzing and assessing the development trends of cutting-edge technologies and potential application scenarios, identifying and evaluating the future direction of vehicle standardization development, promoting the formulation and release of standard sub-systems for automotive AI, Solid State Battery, electric vehicle battery swapping, and initiating the construction of standard systems for new fields such as data governance and application, while conducting advanced research on standardization needs for new business formats like flying cars.
Hong Kong stock announcement for investment | Shanghai Aunt plans to globally offer 2.41134 million shares listed in Hong Kong, introducing Yongfeng Holdings and Huazhi as cornerstone investors.
Auntie Hu Shanghai (02589) plans to globally issue 2.41134 million shares listed in Hong Kong, introducing Yingfeng Holdings and China Holdings as cornerstone investors;
Express News | Ascentage Pharma Presented Results From Five Preclinical Studies During Poster Presentations At The 2025 American Association For Cancer Research Annual Meeting
Ascentage Pharma Group International (HKG:6855) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected
[2025 ASCO] Ascentage Pharma's core product APG-2575 received a verbal presentation, and the company had a total of two clinical studies selected.
Rockville, Maryland, USA and Suzhou, China, April 24, 2025 /PR Newswire/ -- Ayshan Pharma, a leading Biomedical company committed to developing Innovative Drugs in areas like blood cancers (Nasdaq code: AAPG; Hong Kong Stock Exchange code: 6855), today announced that results from two clinical studies of its key apoptosis pipeline products, the Bcl-2 selective inhibitor Lisaftoclax (APG-2575) and the MDM2-p53 inhibitor Alrizomadlin (APG-115), were selected for the 2025 American Clinical Oncology.
ASCENTAGE-B (06855) has two studies selected for the 2025 Annual Meeting of the American Society of Clinical Oncology, including an oral presentation of Lisaftoclax (APG-2575).
ASCENTAGE-B (06855) has released an announcement regarding the company's apoptosis pipeline key product, a Bcl-2 selective inhibitor...
